Purpose of review
Animal models published within the past 18 months on asthma, food allergy and anaphylaxis, all conditions of rising public health concern, were reviewed.

Recent findings
While domestic animals spontaneously develop asthma, food allergy and anaphylaxis, in animal models, divergent sensitization and challenge routes, dosages, intervals and antigens are used to induce asthmatic, food allergic or anaphylactic phenotypes. This must be considered in the interpretation of results. Instead of model antigens, gradually relevant allergens such as house dust mite in asthma, and food allergens like peanut, apple and peach in food allergy research were used. Novel engineered mouse models such as a mouse with a T-cell receptor for house dust mite allergen Der p 1, or with transgenic human FcγR genes, facilitated the investigation of single molecules of interest. Whole-body plethysmography has become a state-of-the-art in-vivo readout in asthma research. In food allergy and anaphylaxis research, novel techniques were developed allowing real-time monitoring of in-vivo effects following allergen challenge. Networks to share tissues were established as an effort to reduce animal experiments in allergy which cannot be replaced by in-vitro measures.

Summary
Natural and artificial animal models were used to explore the pathophysiology of asthma, food allergy and anaphylaxis and to improve prophylactic and therapeutic measures. Especially the novel mouse models mimicking molecular aspects of the complex immune network in asthma, food allergy and anaphylaxis will facilitate proof-of-concept studies under controlled conditions.

Keywords
anaphylaxis, asthma, FcγR, food allergy, IgE, mouse model, rhinitis

INTRODUCTION
Animal models have significantly contributed to the understanding of the three allergy problems with the most destructive outcomes being asthma, food allergy and anaphylaxis. Although mice are the most commonly used species, the immunological limitations of this model have been increasingly realized, prompting for instance the generation of transgenic mice expressing IgE-receptors on cells that are relevant in human allergy, such as dendritic cells or eosinophils. Surprisingly, current studies with such models even suggested an anti-inflammatory role of IgE/FcγRII signals [1], reviewed in [2]. The situation in mice is also complicated by the fact that mouse FcγRII acts as IgE-receptor similar to human FcγRI and contributes in IgE-induced lung inflammation [3]. More rarely, other allergy models than mice were used, for instance rats and guinea pigs [4,5], or piglets [6], especially for answering pharmacologic questions. In the investigated time period of this review (18 months back), no research articles involving monkey or nonhuman primates were published.

As companion animals may spontaneously develop skin (dogs, cats and horses), respiratory (cats and horses) and food allergies (dogs, cats, horses) like human patients, their inclusion as animal model ‘patients’ is increasingly encouraged [7]. Although in these animals little is known about...
the eliciting specific allergen molecules [8,9], the immune mechanisms relevant for allergies in dog, cat and horses are more similar to humans than any rodent models. These facts prompted experimental approaches including models for food sensitization [10] or for sublingual allergen-specific immunotherapy [11], up to clinical comparative investigations in animal patients, which are very similar to humans [12,13]. Technically, however, all investigations in animals are regulated by the animal experimentation directives [14]. This may prevent animal owners from participation in trials.

Therefore, and for practical reasons, most current work on animal models discussed below derives from murine studies and allows comparisons with previous mouse murine studies, but there are continuous efforts to advance these artificial models in terms of immune parameters and technical readouts.

**Asthma models: using antigens or allergens?**

Asthma in humans develops due to chronic inflammation of the airways, in contrast to murine asthma models that only develop acute airway inflammation [15]. Nevertheless, most of our knowledge about the pathogenesis relies heavily on available mouse models.

Ovalbumin from egg is often used as a model antigen, although it is not a respiratory allergen for humans. The rationale is that a great number of transgenic models have ovalbumin-specific immune cells, allowing elegant and precise studies of the immunological machinery. It should be noted, however, that also transgenic mice exist which specifically react to more relevant allergens, like the 1-DER mice expressing the T-cell receptor specific for the major house dust mite allergen Der p 1 from *Dermatophagoides pteronyssinus* [16]. Recent reports, all using ovalbumin have shown aggravation of asthma by pentraxin 3 [17], prostaglandin E2 [18], IL-15-deficiency [19] or suppression of asthma by anti-inflammatory protein 2 from hookworms [20**], natural killer (NK) receptor 1 [21] and inhibition of hypoxia inducible factor-1α [22]. Sensitization with ovalbumin was usually performed by the intraperitoneal route, which, though valid, hardly represents the natural respiratory sensitization process in humans or animals. Allergen challenge to induce the pulmonary phenotype is conducted intranasally or by aerosolization in nebulization chambers (see below, Table 1).

An increasing number of current studies tried to mimic the natural sensitization course, mainly using allergen extracts of house dust mites [23–27, 28**,29–34], but also from other relevant sources like from the fungus *Alternaria alternata* [35] and cockroaches [36,37].

Also transfer models were employed, in which human blood immune cells stimulated in-vitro with allergens are transferred to immune-deficient mice to mimic human asthma [38].

Considering the increasing number of molecular allergens available, more studies should be done with ‘true’ allergens which, however, will require the creation of new specific reagents and models.

**Pathophysiology associated with immune changes in asthma models**

As a readout for airway hyperreactivity and lung resistance, mice were exposed to increasing concentration of methacholine and monitored either by whole-body plethysmography (Fig. 1, from [39]) [29,34,40] or by surgically implanted means [23,24,27]. Studies investigating the mechanisms at the very start of allergic sensitization demonstrated that B-cells are dispensable for the primary CD4+ T-cell response, but crucial for expansion of primed Th2 cells and generation of central memory [28**]. ILC 2 were not an early source of Th2 cytokines, but contributed to allergic inflammation [26] together with IL-33 derived from monocytes [24], IL-23 secreted by bronchial epithelial cells [32], placentation growth factor [27] and lysophophatidylcholine [36].

Th2 and Th17 inflammatory pathways seemed to be reciprocally regulated in asthma [41]. On the other hand, CpG-oligodeoxynucleotides [37], STAT3 inhibition [42], CB2 receptors on NK cells [31] or secretoglobin superfamily protein SCGB3A2 [33] suppressed allergen-induced asthma in mice. Thus, the investigated factors illustrate that asthma can be counterregulated by reinforcing tolerance or skewing Th2-based asthma towards Th1 or Th17.
Models of severe asthma

Asthmatic patients immunologically cluster either in Th2-high, Th17-high or Th2/17 subgroups [41]. Severe asthma patients usually have high IFN-γ and low Th2 and IL-17 responses and do not respond to systemic corticosteroids [23]. Thus, models for severe asthma have been developed, in which cyclic-di-GMP (Guanosinmonophosphat), a second messenger produced by many pathogenic bacteria and being a strong Th1-Th17 adjuvant, was coapplied with the allergen extract during sensitization [23]. Similarly, severe asthma was also induced by infecting mice during the sensitization phase with influenza virus [30].

Food allergy models

Novel models: humanized and knockout

As a novel food allergy model, NOD-scid-γc−/− mice with a human membrane-bound stem cell factor transgene were engrafted with human cord-blood derived CD34+ hematopoietic stem cells (HSCs) [44**]. When peanut butter was given intragastrically, HSC-engrafted mice formed peanut-specific serum-IgE, systemic anaphylaxis (body temperature drop and human serum tryptase) and human IgE+ mast cells were observed in the small intestine, the spleen and the skin.

Using this model, CD4+CD25+ splenic T cells stimulated with or without allergen and/or recombinant glycoprotein A repetitions predominant (GARP) were transferred into the mice [45]. After allergen challenge, mini-endoscopy revealed that Tregs were responsible for inhibition of human allergen-specific IgE and allergen-specific gut inflammation. This inhibitory effect of Tregs was abolished when Treg-inducing protein GARP was blocked.

In another study, the phenomenon why Wiskott–Aldrich syndrome (WAS) patients develop higher rates of food allergy was investigated in a WAS protein-deficient mouse model. The results revealed that WAS protein expressed in Foxp3+...
T cells has a critical function in the control of immune tolerance to chow antigens, such as soy and wheat, and thus maintenance of intestinal tolerance [46]. In summary, novel humanized mouse models confirmed the impact of Foxp3+ Tregs in tolerance induction to food.

**Other animal models of food allergy**

In addition to mouse and rat models, all relying on diverse sensitization methods, also pigs, dogs or sheep are used in food allergy research (reviewed by [47]). Epicutaneous sensitization was established in Beagles, where peanut paste was applied to normal and atopic dogs (each group n = 5), resulting in serum-IgE in all atopic vs. two control dogs [10]. After oral challenge, pruritic dermatitis, clinical symptoms scores, eosinophilic dermatitis and IgE-positive cells in skin were significantly higher in atopic dogs. This model is useful to mimic food-aggravated atopic dermatitis rather than gastrointestinal symptoms.

**Microbial compounds, RNA and vitamins**

To study the influence of microbial products, Li et al. [48] stimulated B cells with recombinant bacterial flagellin together with IL-4 as Th2-cytokine. In-vitro, flagellin suppressed expression of B-cell lymphoma-6 (Bcl6), a transcription factor repressing IgE-switch in B cells. Exposure to flagellin together with IL-4 induced IgE, while flagellin or IL-4 alone did not. In a wild-type mouse model, ovalbumin induced higher specific IgE, mast cells in intestinal mucosa and anaphylactic temperature drop when coapplied with flagellin. The same protocol in flagellin-receptor TLR-5−/− animals prevented these symptoms.

Micro-RNA can also regulate immune responses. B cells of ovalbumin-sensitized mice expressed high levels of the micro RNA miR-19a in the intestinal mucosa, in parallel with low levels of IL-10 [49]. Accordingly, addition of IL-4 increased the expression of miR-19a and suppressed IL-10 also in-vitro.

The physiologically observed neonatal inefficiency to induce oral tolerance to ovalbumin was studied in the context with vitamin A [50]. In neonatal animals, antigen transfer was markedly increased through the gut barrier, and only from the 3rd week of life on, animals were able to establish oral tolerance. The newborn mice showed a specific deficiency of retinaldehyde dehydrogenase expression in CD103+ dendritic cells (DC) of mesenteric lymph nodes associated with a reduced ability for antigen-specific T-cell activation, with retinol serum levels three times lower than in adults. When vitamin A was supplemented, oral tolerance could be induced right from birth. Therefore, bacterial compounds such as flagellin and micro-RNAs may potentiate food allergy, while vitamin A seems important for tolerance induction, at least in young age.

**Novel approaches to treat food allergies**

Oral treatment of peanut-allergic C3H/HeJ mice with CpG/peanut-poly(lactic-co-glycolic acid) nanoparticles as novel carrier system protected them from anaphylaxis, decreased peanut-specific IgE/IgG1 and Th2 cytokines [51], in accordance with previous own studies [52].

Antihuman IgE antibodies were used in a novel humanized murine model of peanut allergy: PBMC from human peanut-allergic donors were transferred into NOD−/− scid II2Rγnull mice, followed by an intraperitoneal challenge with peanut extract [53]. As therapy, an adeno-associated viral vector coding for a full-length, high-affinity, anti-human IgE antibody derived from the Fab-fragment of Omalizumab was applied once i.v. and significantly reduced specific and total serum IgE, free IgE, plasma histamine, clinical anaphylaxis and prolonged survival times.

Low-dose human recombinant IL-2 as survival factor for Tregs was injected in an ovalbumin- or peanut-allergic mouse model [54]. It prevented food allergy symptoms, anaphylactic body temperature drop, decreased serum mast cell protease-1 (MCP-1) and IL-5 in mesenteric lymph nodes and increased ovalbumin-specific IFN-γ production in mesenteric lymph nodes and Peyer’s patches. Reduction of symptom scores was only effective after about 2 weeks. Anti-CD25 mAb treatment proved the protective role of Tregs in this model.

Mucosal mast cells (MMCs) are positively correlated with diarrhea and anaphylactic symptoms in murine food allergy. In ovalbumin-sensitized mice [55], pharmacologic inhibition of Notch-signaling by a γ-secretase-inhibitor suppressed food antigen-induced mast cell hyperplasia in the intestinal tract. Only 30% of treated vs. 89% of control animals showed allergic diarrhea.

A recombinant hypoallergenic mutant of the major carp allergen Cyp c 1 (mCyp c 1) was used to produce antisera in rabbits or mice [56]. When mice were sensitized to Cyp c 1 or carp-extract and received the antisera, allergic symptoms after oral challenge with Cyp c 1 and carp extract were markedly reduced. The induced specific IgG1 also reduced Cyp c 1-specific degranulation of IgE-loaded rat basophilic leukemia cells by 95%.

Plasmid DNA encoding the peanut-protein (p) Ara h 2 or pAra h 2 mixed with poly-L-lysine were injected intradermally either before or after sensitization with Ara h 2 [57]. The treatment containing
poly-L-lysine was more effective in preventing specific serum antibodies and temperature drop upon challenge when applied before sensitization, inducing CD207+ DCs in draining lymph nodes of skin, CD25+ Foxp3+ Treg cells in lymph nodes and spleen, as well as IFN-γ and IL-10 in splenocytes.

The natural molecule diosgenin from Chinese yam was administered daily to ovalbumin-sensitized BALB/c mice concomitantly with repeated ovalbumin challenges and increased the number of Th1-like Treg cells (Foxp3+), but coexpressing Th1 markers like CCR5, CXCR3, IFN-γ and T-bet) in the intestine, as well as in Peyer’s patches [58].

Another natural molecule, baicalein (5,6,7-trihydroxyflavone) from Baikal skullcap (Scutellaria baicalensis) used in Traditional Chinese Medicine, supported integrity of intestinal tight junctions and prevented uptake of antigens and subsequent food allergy [59]. In an ovalbumin-food allergy mouse model, baicalein – an agonist of the aryl hydrocarbon receptor – reduced allergic symptoms (diarrhea, anaphylactic response, body temperature drop, serum IgE and effector T cells), whereas TGF-β was upregulated. As safety in food allergy therapy is a major concern, strategies to reduce the allergenicity of the therapeutic allergen by encapsulation or application of hypoallergens – besides inhibition of IgE pathways – may be most promising.

Anaphylaxis models

Allergens and routes investigated

Anaphylaxis models are mostly used in food allergy research with paradigmatic allergens like ovalbumin and intraperitoneal injections followed by oral challenges. A recent study used peach allergen Pru p 3 with lipopolysaccharide as adjuvant for intranasal sensitization, and anaphylaxis could be elicited by intraperitoneal challenge [60]. The authors suggested this model to be suitable for testing immunotherapeutic strategies. In another model hazelnut was applied orally and intraperitoneally. Usage of the Th2-adjuvant aluminium hydroxide (alum) led to stronger anaphylactic responses than using Staphylococcal enterotoxin B as adjuvant, which could in fact be therapeutically addressed by proteasome inhibitor bortezomib, reducing IgE and the B-cellular arm [61]. The question of the participation of IgG in the observed reactions was not addressed in this model.

PR-10 family members Bet v 1 from birch and Mal d 1 from apple induce clinically cross-reactive IgE in humans. To address whether allergen-specific immunotherapy (AIT) may affect cross-sensitization, mice were serially sensitized to both molecules with alum intraperitoneally up to a level when Mal d 1 elicited anaphylaxis. When mice then were subcutaneously treated with birch pollen extract adsorbed to alum, like in some human AIT formulations, this reduced the anaphylactic response [62]. Instead of causal treatment, histamine-1-receptor antagonist loratadine and histamine-4-receptor antagonist JNJ7777120 protected peanut-sensitized mice from intestinal anaphylaxis, potentially via preventing intestinal DC accumulation and antigen presentation to T cells [63]. Along this line, another study suggested that histamine-4-receptor antagonist JNJ28307474 should be applied already during the sensitization process to prevent allergy [64].

Taken together, only one of the above studies made efforts to truly mimic the oral sensitization route or used oral challenge with a food allergen, and all used Th2 adjuvants to induce anaphylaxis.

Addressing IgG mechanisms of anaphylaxis

To exclude any biases in terms of induced antibody isotypes in anaphylaxis models (see below), an adjuvant-free sensitization protocol was developed using the intraperitoneal route and ovalbumin [65*]. Knockout models indicated that the anaphylactic drop of body temperature depended on mouse FcγRI, FcγRIII and γ-chain FcRγ, whereas FcγRIV related to inflammation only [65*]. In this model, macrophages and neutrophils turned out to be less important in anaphylaxis than mast cells.

IgG-mediated anaphylaxis has recently become an emerging concern in humans too and can be mimicked by mouse models [66], in which besides IgE, also IgG (via FcγRIV) may act anaphylactogenic [3]. Different mouse IgG subclasses, however, have different effects depending on the used IgG receptor. The tested mouse IgG1 turned out to be exclusively activating and anaphylactogenic when triggered by the model allergen trinitrophenyl-bovine serum albumin, whereas IgG2a and IgG2b also bound to the inhibitory FcγRIIB receptor. This suggested that the sum of these reactions may decide on the anaphylaxis [67*]. Efforts have been done to translate these findings into the human setting, in which four IgG subclasses complicate the events. A transgenic mouse was generated with human hFcγR genes (encompassing activating hFcγRIIA, hFcγRIIIA, hFcγRIIB and inhibitory hFcγRIIB) being inserted into the corresponding mouse locus. Experiments with FcγR locus-switched mice injected with human heat-aggregated intravenous immunoglobulins suggested that despite the presence of inhibitory FcγRIIB, the activating receptors dominated the outcome of the anaphylaxis experiment [68**].
Percutaneous sensitization and anaphylaxis

Also percutaneous exposure to food, especially in atopic dermatitis, may lead to sensitization, priming or boosting of existing allergy. The role of IL-33 binding to the IL-33 receptor ST2 (expressed in human and mouse skin) to trigger anaphylactogenic Th2 responses was investigated. Wild-type, ST2-deficient and mast cell-deficient KitW-sh/W-sh mice were percutaneously sensitized to ovalbumin and orally challenged [69]. Although food-allergic wild-type mice experienced anaphylaxis, it was attenuated in ST2-deficient and in ST2-blocked animals, and abrogated in mast cell-deficient KitW-sh/W-sh mice. The study highlighted the importance of IL-33 and mast cells to trigger anaphylaxis and might lead to novel anti-IL-33 therapeutics in humans [69]. Interestingly platelets, which participate in the anaphylactic reaction, have proven a significant source of IL-33 in humans as well as in an airway eosinophilia model in mice [70].

Novel readout methods

Following the 3R rules (replacement, reduction and refinement of animal experiments), efforts are done to minimize the number of animals used in the experiments, for instance by sharing tissues in networks as SEARCH [71]. However, in-vivo anaphylaxis models are needed in allergy research and for safety monitoring in vaccine development. Following single animals continuously over time during a reaction reduces the number of animals needed during an experiment.

The major anaphylaxis readouts in mouse models are drop of body temperature, reduction of physical mobility, eventually diarrhea and the elevation of MCP-1 levels released from anaphylactic mast cells. Telemedical devices can be surgically implanted into mice that allow the live reading of temperature, but this invasive method requires an experienced hand. Alternative methods based on imaging can only be done after isoflurane anesthesia and are usually not suitable for monitoring animals in motion [72]. A novel device and software has been developed that allows the noninvasive monitoring of surface body temperature and thereby also horizontal and vertical movements by imaging heat pictures (Fig. 2) [73]. Proof-of-concept studies were successful using casein, peanut and ovalbumin as food allergens for sensitization of BALB/c mice.

CONCLUSION

Summarized, a plethora of current murine asthma models helped us to an improved understanding of the pathophysiology of human asthma, food allergy and anaphylaxis. The routes, dosages, intervals and antigens used for sensitization, or used for challenges to induce an asthmatic (Table 1) or food allergic phenotype (Table 2), are, however, very diverse and should be considered in the interpretation.
Increasingly, more relevant allergens such as house dust mite in asthma, and as peanut, apple or peach in food allergy research are used. In-vivo readouts are important to assess the clinical relevance. This is done by whole-body plethysmography in asthma research (Fig. 1) [39]. In food allergy and anaphylaxis research, novel techniques were developed allowing the in-vivo monitoring of effects by allergen challenges, and, in accordance with the 3R principle, networks are formed to share tissues [70]. Future research directions may address the development of novel engineered mouse models facilitating the investigation of single-target molecules, whereas domestic animals represent natural animal models,

| Allergen | Sensitization | Challenge | AHR   | Reference |
|----------|---------------|-----------|-------|-----------|
| Alternaria alternata extract | iTreg cells transferred i.v. into Rag2-/ mice followed by i.n. with IL-33 or 25 µg Alternaria alternata | n/a | i.t. | [35] |
| Amb a 11 | 2×10 µg Amb an 11 i.p. | 4×10 mg Amb a 1 +100 µg LPS aerosol, 20 min | WBP | [40] |
| Birch allergen | 1×5 Mio PBMCs + 20 µg birch allergen + 10 ng IL-4 i.p. 1×20 µg birch allergen + 10 ng IL-4 | 3×20 µg birch allergen | i.t. | [38] |
| CE | 3×10 µg CE i.p. | 3×10 µg CE i.n. | WBP | [36] |
| CE | 6×120 µg CE +3 µg CpG-ODN i.n. | n/a | WB | [37] |
| HDM | 1×200 µg, 2×100 µg i.n. | 4 cycles: 2×50 µg HDM i.n. | WBP | [41] |
| HDM | Severe asthma: 3×25 µg HDM + 7 µg c-di-GMP | 3 cycles with: 1×25 µg HDM + 5 µg cyclic-dl GMP and 2×25 µg HDM i.n. | i.t. | [23] |
| HDM | 3×25 µg HDM i.n. | 3×5 µg HDM i.n. | i.t. | [24] |
| HDM | 3×25 µg HDM i.n. | n/a | WBP | [25] |
| HDM | 1×1 µg HDM i.n. | 5×10 µg HDM i.n. or 1×100 µg HDM i.n. | n/a | [26] |
| HDM | 2×10 µg HDM i.p. | 100 µg i.t. on day 14 +19 | i.t. | [27] |
| HDM | 1×1 µg crude HDM i.t. | 2×10 µg HDM i.n. | j.v., WBP | [28**] |
| HDM | 5 cycles: 5×25 µg HDM i.n. | n/a | WBP | [29] |
| HDM | 5 cycles: 3×25 µg HDM i.n. 1×influenza virus x31 i.n. | n/a | WBP | [30] |
| HDM | 1×100 µg HDM i.n.; 4×50 µg HDM i.n. | n/a | n/a | [31] |
| HDM | 4×50 µg HDM i.n. | 3×50 µg HDM i.n. | n/a | [32] |
| HDM | 5 cycles: 5×25 µg HDM i.n. | n/a | n/a | [33] |
| HDM | 3 cycles: 5×40 µg HDM i.n. and 1×320 µg HDM i.p. | n/a | n/a | [42] |
| HDM + DEP | 3×1 µg HDM +25 µg DEP i.p. | n/a | WBP | [34] |
| KLH | 3 cycles: 2×5 µg KLH±10 µg acrolein, 2 cycles: 2×10 µg KLH±20 µg acrolein i.n. | 2×10 µg KLH i.n. | WBP | [74] |
| OVA | 2×OVA + Alum i.p. | 2×OVA i.n. | i.t. | [17] |
| OVA | 2×20 µg OVA + Alum i.p. | 5×0.2% OVA aerosol, 20 min | i.t. | [20**] |
| OVA | 3×25 µg OVA +2 mg Alum i.p. | 3 or 7×1% OVA aerosol, 1 h | n/a | [19] |
| OVA | 2×OVA i.p. | 5×OVA i.n. | i.t. | [22] |
| OVA | 2×OVA i.p. | 2×25 µg OVA i.n. | n/a | [21] |
| OVA | 3×20 µg Ova + Alum i.p. | 3×1% OVA aerosol, 30 min | i.t. | [18] |

AHR, airway hyperreactivity; CE, cockroach extract; DEP, diesel exhaust particles; HDM, house dust mite extract; i.n, intranasal; i.p., intraperitoneal; i.t. intratracheal; i.v., intravenous; j.v., jugular vein; KLH, keyhole limpet hemocyanin; n/a, not applicable.; OVA, ovalbumin; WBP, whole-body plethysmography.
Table 2. Sensitization, challenge and readout principles in food allergy models

| Allergen       | Sensitization                                                                 | Challenge                                                                 | Readout                                                                 | Ref. |
|---------------|------------------------------------------------------------------------------|--------------------------------------------------------------------------|------------------------------------------------------------------------|------|
| Chow components (wheat, soybean, wheat middlings, yellow corn, fish meal) | Was−/−, Was−/− Il10−/−, Was−/− Rag2−/− mice: none (spontaneous sensitization) | None (spontaneous sensitization) or starving for 3h then fed 12.5 mg soy protein in 300 μl PBS | Surface LAMP-1, Intestinal mast cell expansion, Serum levels of mast cell protease 1 (MCPT1), body temperature by transponder | [46] |
| Cyp c 1; Hypoallergenic mCyp c 1; carp extract | C3H/HeJ mice: 5× i.g. weekly 100 mg rCyp c 1 + 20 mg cholera toxin in 200 ml 0.2 mol bicarbonate buffer (pH 9) 20 mg hypoallergenic mCyp c 1 + Alum s.c. 6 times every month; Carp extract–sensitized C3H/HeJ, 600 ml of heat-inactivated mCyp c 1–specific mouse antisera i.p. | i.g. 100 mg rCyp c 1 i.g. 10 mg carp extract | Symptom score | [56] |
| OVA           | BALB/c mice: 2× i.p. 50 mg of OVA + Alum + magnesium hydroxide              | 5× i.g. 50 mg of OVA every other day | Diarrhea, rectal temperature | [55] |
| OVA           | BALB/c mice: gavaged daily with diosgenin                                    | repeatedly i.g. OVA                                                     | Foxp3+ Treg cells expressing Th1-type transcription factors, cytokines, chemokines in intestine, mRNA expression of chemokines corresponding to Th1-like Treg cells | [58] |
| OVA           | BALB/c mice: 2× i.p. 20 μg OVA + Alum                                       | 5× orally 50 mg OVA every 3 days; Basoceilin (20 mg/kg) orally administered daily from day 28–40 | Diarrhea, anaphylaxis, rectal temperature | [59] |
| OVA           | BALB/c mice: 2× i.p. 10 mg OVA + Alum                                       | OVA p.o. (20 mg/mouse), 5× within a 10-day period | Rectal body temperature, clinical score (diarrhea severity, appearance of hirsute pelage) | [54] |
| OVA           | OVA (2 mg) i.g. 3×/week for lactating mothers 3 weeks after delivery or during lactation period ± VFA suplementation by maternal vitamin A enriched diet from 2 days before delivery until the end of first week | 6–8-week-old adult mice: allergic airway inflammation to OVA by i.p. 1 mg OVA + Alum on days 0 and 7; day 17–21 mice exposed to OVA (0.5%) aerosols for 20 min in nebulizer | Serum OVA-specific IgE, IgA, eosinophil BAL; lung cell cytokine secretion; ex vivo gut permeability; small intestine histology; serum retinol levels | [50] |
| Peanut extract | NOD-scid IL2Rgamma−/− mice: transferred i.p. 3 × 10⁷ blood mononuclear cells from peanut allergic donors + 100 mg crude peanut extract; i.p. 2 × 100 mg of crude peanut extract; therapy: AAVh.10 anihIgG (10¹ genome copies) at week 3, reconstituted with human donor blood mononuclear cells at week 0 | i.g. 300 mg crude peanut extract at weeks 5–10 | Clinical score, anaphylaxis score, histamine in plasma, PCA | [53] |
| Peanut butter | huNSG mice: i.g. 22.5 mg (15 mg protein) skimpy creamy peanut butter in 2.5 mol sodium bicarbonate, pH 8.0, weekly for 8 weeks | Fed 350 mg peanut butter in 0.2 mol sodium bicarbonate | Temperature measurements using s.c. microchip transponders; PNS specific human IgE in serum; tissue mast cell expansion | [44*] |
| Peanut extract, pAra h 2, PLL-pAra h 2 | BALB/c mice: i.d. PLL-pAra h 2 or pAra h 2 (25 μg pAra h 2 DNA) 3×, followed i.p. 2.5 μg purified Ara h 2 + Alum | i.p. 5 mg CPE | Rectal temperature | [57] |
Papers of particular interest, published within the annual period of review, have been highlighted as:

+ special interest
++ outstanding interest

1. Plazier B, Baker K, Vera MP, et al. Dendritic cell-bound IgE functions to restrain allergic inflammation at mucosal sites. Mucosal Immunol 2015; 8:516–532.
2. Plazier B, Stout M, Fiebig E. Functions of dendritic-cell-bound IgE in allergy. Mol Immunol 2015; 68:116–119.
3. Mancardi DA, Iannasci B, Hoos S, et al. FcgammaRIV is a mouse IgE receptor that resembles macrophage FcεRI in humans and promotes IgE-induced lung inflammation. J Clin Invest 2008; 118:3738–3750.
4. Cordoba-Rodriguez G, Vargas MH, Ruiz V, et al. Allergic sensitization modifies the pulmonary expression of 5-hydroxytryptamine receptors in guinea pigs. Respir Physiol Neurobiol 2016; 223:9–15.
5. Xu Y, Kang T, Dou D, Kuang H. The evaluation and optimization of animal models for asthma, food allergy and anaphylaxis. Mol Immunol 2015; 68:116–119.
6. Dendritic cell-bound IgE functions to restrain allergic inflammation at mucosal sites. Mucosal Immunol 2015; 8:516–532.
7. Jensen-Jarolim E, Einhorn L, Herrmann I, et al. Pollen allergies in humans and their dogs, cats and horses: differences and similarities. Clin Transl Allergy 2015; 5:16.
8. Mueller RS, Janda J, Jensen-Jarolim E, et al. Allergens in veterinary medicine. Allergy 2016; 71:27–35.
9. Pali-Schott I, De Lucia M, Jackson H, Janda J, Mueller R, Jensen-Jarolim E. Comparing immediate type food allergy in humans and companion animals – definition of knowledge gaps: EAACI position paper. approved by ExCom, in submission.
10. Mursela B. Experimental model for peanut allergy by epicutaneous sensitization in atopic beagle dogs. Exp Dermatol 2015; 24:711–712.
11. Plazier B, Baker K, Vera MP, et al. Dendritic cell-bound IgE functions to restrain allergic inflammation at mucosal sites. Mucosal Immunol 2015; 8:516–532.
12. Mancardi DA, Iannasci B, Hoos S, et al. FcgammaRIV is a mouse IgE receptor that resembles macrophage FcεRI in humans and promotes IgE-induced lung inflammation. J Clin Invest 2008; 118:3738–3750.
13. Jensen-Jarolim E, Einhorn L, Herrmann I, et al. Pollen allergies in humans and their dogs, cats and horses: differences and similarities. Clin Transl Allergy 2015; 5:16.
14. Mueller RS, Plazzier B, Baker K, Vera MP, et al. Dendritic cell-bound IgE functions to restrain allergic inflammation at mucosal sites. Mucosal Immunol 2015; 8:516–532.
15. Mancardi DA, Iannasci B, Hoos S, et al. FcgammaRIV is a mouse IgE receptor that resembles macrophage FcεRI in humans and promotes IgE-induced lung inflammation. J Clin Invest 2008; 118:3738–3750.
16. Plazier B, Baker K, Vera MP, et al. Dendritic cell-bound IgE functions to restrain allergic inflammation at mucosal sites. Mucosal Immunol 2015; 8:516–532.
17. Mancardi DA, Iannasci B, Hoos S, et al. FcgammaRIV is a mouse IgE receptor that resembles macrophage FcεRI in humans and promotes IgE-induced lung inflammation. J Clin Invest 2008; 118:3738–3750.
18. Jensen-Jarolim E, Einhorn L, Herrmann I, et al. Pollen allergies in humans and their dogs, cats and horses: differences and similarities. Clin Transl Allergy 2015; 5:16.
19. Mueller RS, Janda J, Jensen-Jarolim E, et al. Allergens in veterinary medicine. Allergy 2016; 71:27–35.
20. Pali-Schott I, De Lucia M, Jackson H, Janda J, Mueller R, Jensen-Jarolim E. Comparing immediate type food allergy in humans and companion animals – definition of knowledge gaps: EAACI position paper. approved by ExCom, in submission.
21. Mursela B. Experimental model for peanut allergy by epicutaneous sensitization in atopic beagle dogs. Exp Dermatol 2015; 24:711–712.
22. Plazier B, Baker K, Vera MP, et al. Dendritic cell-bound IgE functions to restrain allergic inflammation at mucosal sites. Mucosal Immunol 2015; 8:516–532.
23. Mancardi DA, Iannasci B, Hoos S, et al. FcgammaRIV is a mouse IgE receptor that resembles macrophage FcεRI in humans and promotes IgE-induced lung inflammation. J Clin Invest 2008; 118:3738–3750.
24. Jensen-Jarolim E, Einhorn L, Herrmann I, et al. Pollen allergies in humans and their dogs, cats and horses: differences and similarities. Clin Transl Allergy 2015; 5:16.
25. Mueller RS, Plazzier B, Baker K, Vera MP, et al. Dendritic cell-bound IgE functions to restrain allergic inflammation at mucosal sites. Mucosal Immunol 2015; 8:516–532.
26. Mancardi DA, Iannasci B, Hoos S, et al. FcgammaRIV is a mouse IgE receptor that resembles macrophage FcεRI in humans and promotes IgE-induced lung inflammation. J Clin Invest 2008; 118:3738–3750.
27. Plazier B, Baker K, Vera MP, et al. Dendritic cell-bound IgE functions to restrain allergic inflammation at mucosal sites. Mucosal Immunol 2015; 8:516–532.
28. Mancardi DA, Iannasci B, Hoos S, et al. FcgammaRIV is a mouse IgE receptor that resembles macrophage FcεRI in humans and promotes IgE-induced lung inflammation. J Clin Invest 2008; 118:3738–3750.
29. Jensen-Jarolim E, Einhorn L, Herrmann I, et al. Pollen allergies in humans and their dogs, cats and horses: differences and similarities. Clin Transl Allergy 2015; 5:16.
This outstanding article describes the use and efficacy of the anti-inflammatory protein 2 from house mite as a novel agent for allergen immunotherapy in an asthma model.

1. Elhaik Goldman S, Moshkovits I, Shemesh A, et al. Natural killer receptor 1 regulates regulatory T cell responses that limit allergic airway inflammation in a murine model. Allergy 2016; 71:154–162.

2. Dewitz C, McEachern J, Shi N, et al. Hypoxia-inducible factor-1alpha promotes Th2 cell differentiation in house mite-induced asthma. J Clin Invest 2016; 126:571–584.

3. Eiymo Mwa Mpollo MS, Brandt EB, Shanmukhappa SK, et al. Placenta growth factor augments airway hyperresponsiveness via leukotrienes and IL-13. J Clin Invest 2016; 126:571–584.

4. Eymo Mwa Mpollo MS, Brandt EB, Shanmukhappa SK, et al. Placenta growth factor augments airway hyperresponsiveness via leukotrienes and IL-13. J Clin Invest 2016; 126:571–584.

5. Dewitz C, McEachern J, Shi N, et al. Hypoxia-inducible factor-1alpha promotes Th2 cell differentiation in house mite-induced asthma. J Clin Invest 2016; 126:571–584.
66. Khodoun MV, Strait R, Armstrong L, et al. Identification of markers that distinguish IgE- from IgG-mediated anaphylaxis. Proc Natl Acad Sci U S A 2011; 108:12413–12418.

67. Beutier H, Gillis CM, Iannascoli B, et al. IgG subclasses determine pathways of anaphylaxis in mice. J Allergy Clin Immunol 2017; 139:269–280 e267. This article evidences that the sum of all different IgG subclasses in a complex interplay with FcγRs decide on whether anaphylaxis occurs or not. Considering the novel findings that IgG is involved in human systemic hypersensitivity too, this mouse model is very useful and important.

68. Gillis CM, Jonsson F, Mancardi DA, et al. Mechanisms of anaphylaxis in human low-affinity IgG receptor locus knock-in mice. J Allergy Clin Immunol 2016. [Epub ahead of print] This innovative transgenic mouse model expressing human activating and inhibitory FcγRs genes is a step forward to better understand the effects of human IgG subclasses in anaphylaxis – experiments suggest that in fact activating receptors dominates the outcome.

69. Galand C, Leyva-Castillo JM, Yoon J, et al. IL-33 promotes food anaphylaxis in epicutaneously sensitized mice by targeting mast cells. J Allergy Clin Immunol 2016; 138:1356–1366.

70. Takeda T, Unno H, Morita H, et al. Platelets constitutively express IL-33 protein and modulate eosinophilic airway inflammation. J Allergy Clin Immunol 2016; 138:1395–1403.e1396.

71. Morrissey B, Blyth K, Carter P, et al. The sharing experimental animal resources, coordinating holdings (SEARCH) framework: encouraging reduction, replacement, and refinement in animal research. PLoS Biol 2017; 15:e2000719.

72. Hayashi M, Takai J, Yu L, et al. Whole-body in vivo monitoring of inflammatory diseases exploiting human interleukin 6-luciferase transgenic mice. Mol Cell Biol 2015; 35:3590–3601.

73. Manzano-Szlai K, Pal-Scholl I, Krishnamurthy D, et al. Anaphylaxis imaging: non-invasive measurement of surface body temperature and physical activity in small animals. PLoS One 2016; 11: e0150819.

74. Roth-Walter F, Bergmayr C, Meitz S, et al. Janus-faced acrolein prevents allergy but accelerates tumor growth by promoting immunoregulatory Foxp3+ cells: mouse model for passive respiratory exposure. Sci Rep 2017; In Press.